Here’s why Moderna is sliding

Traders Union
All News
Financial News
Moderna Slides 5.25% Today to $25.74

Highlights

Moderna reported positive interim Phase 3 results for its combined COVID-19 and influenza vaccine, showing strong immune responses in adult participants.
The FDA accepted and granted priority review to Moderna's investigational RSV vaccine for adults 60+, with a regulatory decision expected this year.
Moderna narrowed its quarterly loss due to ongoing vaccine sales and improved cost controls, and settled patent litigation with Johnson & Johnson.

Positive trial results and regulatory progress as drivers of sentiment shift

Moderna announced positive interim Phase 3 results for its combined COVID-19 and influenza vaccine, demonstrating strong immune responses in adult participants. The FDA also accepted and granted priority review to its investigational RSV vaccine for adults aged 60 and older, with a regulatory decision expected this year. Additional developments include a narrowed quarterly loss driven by continued vaccine sales and improved cost controls, as well as a patent litigation settlement agreement between Johnson & Johnson and Moderna.

Anton Kharitonov, expert at Traders Union, notes that Moderna remains technically vulnerable with the share price persistently below major moving averages and prone to sharp pullbacks, as evidenced by today’s 5.25% drop. The fundamental landscape is mixed, as positive vaccine developments have not translated into sustained investor confidence or reversed the prevailing sentiment of caution. "While the headline news is encouraging, the dominance of sellers and persistent technical resistance signal that risk of further downside for MRNA outweighs upside opportunities in the current environment."

Viktoras Karapetjanc, expert at Traders Union, sees several structural positives for Moderna, highlighting the robust clinical progress with both its combined COVID-19/flu vaccine and the RSV regulatory milestone as catalysts for future institutional interest. He believes recent cost controls and partnerships reinforce the company’s longer-term growth story, regardless of temporary technical softness. "With Moderna’s innovative pipeline and strengthened fundamentals, I expect renewed upward momentum and believe the market offers multiple setups for forward-looking investors looking to capitalize on recovery potential."

Jainam Mehta, market strategist, observes that momentum signals are at odds with price action, opening the door for tactical trades as sellers exhaust themselves near recent support. He suggests that sideways consolidation could precede a breakout attempt, especially if price holds above $25.92. "Given current momentum divergences, a contrarian entry above $26.88 could capture any oversold bounce — but traders should stay nimble as the selling pressure has not fully abated."

Technical barriers intensify as momentum signals diverge and selling accelerates

This setup suggests lingering short-term and medium-term pressure from sellers, while the long-term trend remains under pronounced resistance, with immediate dynamic resistance near the Kijun level at $26.68 and MA-20, and support near the MA-50 at $25.92.

Momentum readings present a mixed picture, with daily MACD showing strong buy but a low ADX signaling trend weakness. RSI D1 hovers in neutral territory at 52.46, and Stoch RSI is neutral overall but oversold on shorter timeframes; CCI also stays neutral, while Bull/Bear Power on D1 hints at overbought but shifts to oversold intraday, showing sellers have dominated today’s move. The Awesome Oscillator's neutral setting does not currently add to trend conviction. The stock dropped $1.43 today (down 5.25%) after a slight gap down from the previous close, and the price sits near the lower end of today’s range, with volatility moderate and tone under selling pressure after the open. There is clear divergence between strong daily momentum (MACD buy) and the ongoing rapid intraday sell-off, so caution is warranted as indicators conflict with the current pace of selling.

Previously it was noted that bullish momentum runs into resistance as the stock faces mixed technical signals. Additionally, positive vaccine trial results and advances in mRNA therapies were highlighted as supporting factors for the company's pipeline.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.